TNF inhibitor

Questions discussed in this category

How do you counsel patients who prefer to continue TNFi therapy indefinitely for rheumatoid arthritis despite long-standing remission?

Do you advocate to taper the TNF-i or simply continue to monitor for long term adverse events? This question is part of a collaboration with Rheu...

3 Answers available

Do you stop TNF inhibitors during the third trimester of pregnancy?

2 Answers available

How do you approach the continued use of TNF inhibitors in a patient with inflammatory arthritis who develops a positive dsDNA without clinical evidence of drug-induced lupus?

2 Answers available

What is your preferred infliximab dosing strategy for hidradenitis suppurativa?

2 Answers available

Do you recommend checking anti-drug antibodies for patients on TNF inhibitors?

If so, how would positive levels guide your management?

3 Answers available

What do you use to treat uveitis refractory to conventional synthetic DMARDs and TNF inhibitors?

Are IL-17 or IL-23 inhibitors helpful?

5 Answers available

Papers discussed in this category

Ophthalmology, 2015-05

Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.

Retina,

LONG-TERM OUTCOMES OF RITUXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS POSTERIOR UVEITIS REFRACTORY TO CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY.

Ophthalmic Res, 2018 Apr 10

Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis.

Dev Ophthalmol, 2012 Apr 17

Rituximab for noninfectious uveitis.

Arthritis Rheumatol, 2019 Aug 12

Long-Term Outcome of Ustekinumab Therapy for Behçet's Disease.

American journal of ophthalmology, 2017-11

Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis.

J Am Acad Dermatol, 2019 Mar 11

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

J Am Acad Dermatol, 2019 May 13

Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa.

Dermatology,

Infliximab for the treatment of hidradenitis suppurativa.

Autoimmun Rev, 2012 Nov 30

Immunogenicity and autoimmunity during anti-TNF therapy.

Arthritis research & therapy, 2023 Nov 20

Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review.

Related Topics